Financial calendar for BerGenBio ASA

FINANCIAL YEAR 2020


10.02.2021 - Quarterly Report - Q4


FINANCIAL YEAR 2021

17.08.2021 - Half-yearly Report
25.02.2021 - Annual Report
19.03.2021 - Annual General Meeting

19.05.2021 - Quarterly Report - Q1
16.11.2021 - Quarterly Report - Q3



The dates are subject to change. The time and location of the presentations will
be announced in due time.

For more information, please contact:

ir@bergenbio.com

or visit www.bergenbio.com

About BerGenBio ASA
BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company's proprietary lead candidate, bemcentinib, is a potentially
first-in-class selective AXL inhibitor in a broad phase II clinical development
programme focused on combination and single agent therapy in lung cancer,
leukaemia and COVID-19. A first-in-class functional blocking anti-AXL antibody,
tilvestamab, is undergoing phase I clinical testing. In parallel, BerGenBio is
developing a companion diagnostic test to identify patient populations most
likely to benefit from bemcentinib: this is expected to facilitate more
efficient registration trials supporting a precision medicine-based
commercialisation strategy. 
BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit www.bergenbio.com



This information is published pursuant to the requirements set out in the
Continuing obligations.